Related Experiment Videos

Identification of a novel mutation in patients with medium-chain acyl-CoA dehydrogenase deficiency

B Z Yang1, J H Ding, C Zhou

  • 1Kimberly H. Courtwright & Joseph W. Summers Institute of Metabolic Disease, Baylor University Medical Center, Dallas, Texas 75226, USA.

Insights

A novel mutation, G617T, was found in medium-chain acyl-CoA dehydrogenase deficiency patients. This genetic finding sheds light on unusual disease presentations and potential therapeutic targets.

Area of Science:

  • Biochemistry
  • Genetics
  • Metabolic Disorders

Background:

  • Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is an inherited metabolic disorder affecting fatty acid oxidation.
  • Genetic mutations in the ACADM gene are the primary cause of MCAD deficiency.
  • Typical presentations include hypoglycemia and lethargy during infancy and early childhood.

Observation:

  • Two unrelated patients presented with atypical clinical manifestations of MCAD deficiency.
  • One patient, a 19-year-old female, experienced a severe, fatal illness in adulthood, an unusual outcome for MCAD deficiency.
  • The second patient, a male, presented at 17 months with hypoglycemic seizure and dehydration.

Findings:

  • Sequence analysis identified a novel mutation, G617T in exon 8 of the ACADM gene, leading to an arginine to leucine substitution at codon 206 (R206L).
  • Both patients were found to be compound heterozygous, carrying this novel G617T mutation along with the common A985G mutation.
  • The novel R206L substitution is implicated in the observed severe and atypical clinical phenotypes.

Implications:

  • This discovery expands the spectrum of known ACADM mutations and their associated clinical presentations.
  • Understanding this novel mutation may improve diagnostic strategies for medium-chain acyl-CoA dehydrogenase deficiency.
  • Further research into the functional impact of the R206L mutation could inform therapeutic interventions for MCAD deficiency.

Related Concept Videos